Navigation Links
Amgen Announces 2013 Second Quarter Dividend
Date:3/6/2013

our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign) and difficulties or delays in manufacturing our products. In addition, sales of our products are affected by reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We, or others, could identify safety, side effects or manufacturing problems with our products after they are on the market.  Our business may be impacted by government investigations, litigation and product liability claims. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other
'/>"/>
SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Oct. 1, 2014  Discovery Laboratories, Inc. (Nasdaq: ... awarded a Phase II Small Business Innovation Research ... from the National Institute of Allergy and Infectious ... (NIH) to support the development of the Company,s ... countermeasure to mitigate acute and chronic/late-phase radiation-induced lung ...
(Date:10/1/2014)... As the world takes its first steps ... that this century would mark the beginning of a new ... science. The fact that the world is experiencing a rapid ... scientific community. Almost half of these chronic conditions are due ... with medical care and intervention. While the world is experiencing ...
(Date:10/1/2014)... 2014 Award winning unified communications ... four new-hosted collaboration bundles that combine next generation ... conferencing experiences for low, flat rate fees. ... businesses have optimized solutions to meet their technology ... audio only minutes (1K, 5K, 10K increments) or ...
(Date:10/1/2014)... PHILADELPHIA , October 1, 2014 ... plans to software invited to engage around the theme, ... 29-30     Elsevier ... information products and services, will host a gathering of ... discuss issues and trends impacting healthcare today and in ...
Breaking Biology Technology:Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 2Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 3SoundConnect Launches New Audio, Web and Video Bundles 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3
... Feb. 21 Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ) ... at 8:30 a.m. EST to discuss the fourth quarter ... Michael S. Weiss, Chairman,and Chief Executive Officer of the ... results for this period in a press release to ...
... 13, 2008 at 9:00 am (Eastern) ... am (Pacific) / 9:00 pm (Beijing/Hong Kong), SHANGHAI, ... WX ) ("WuXi PharmaTech" or "the Company"), the ... announced that it will release unaudited,financial results for the ...
... 5% annually over the next five ... to Millennium Research Group, WALTHAM, Mass., Feb. 21 ... the US market for,fixed C-arm systems, comprising units used for ... in 2007 and will,rise to over $1.8 billion by 2012., ...
Cached Biology Technology:Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST 2WuXi PharmaTech Schedules Fourth Quarter and Full Year 2007 Earnings Release on Wednesday, March 12, 2008 2Fixed C-Arms Revolutionize Operating Room Environments 2
(Date:9/30/2014)... suite of perilous threats in today,s ocean. From ... change, fragile coral ecosystems are disappearing at unprecedented ... species of corals surrounding the island of Moorea ... their tropical environment: coral guard-crabs. New research from ... Station scientist Seabird McKeon and the museum,s predoctoral ...
(Date:9/29/2014)... gut bacteria called Clostridium ramosum , coupled with a ... is published this week in mBio , the online ... A research team from the German Institute of Human Nutrition ... including C. ramosum gained weight when fed a ... were less obese even when consuming a high-fat diet, ...
(Date:9/29/2014)... September 29: Between 1970 and 2010 populations of ... globe dropped 52 percent, says the 2014 Living ... (WWF). This biodiversity loss occurs disproportionately in low-income ... high-income countries. , In addition to the precipitous ... to other warning signs about the overall health ...
Breaking Biology News(10 mins):Smithsonian scientists discover coral's best defender against an army of sea stars 2Gut bacteria promote obesity in mice 2Half of global wildlife lost, says new WWF report 2
... This release is available in Spanish . ... emerald ash borer could mean improved traps for monitoring and ... of Agriculture (USDA) entomologist Allard Coss and his colleagues. ... part of a multidisciplinary team of scientists from USDA,s Agricultural ...
... WASHINGTON, April 7, 2011 Moms-to-be long have been ... staying fit during pregnancy is good for both mother and ... that exercising strengthens a fetus, heart control, many pregnant women ... up for prenatal yoga classes; others found new ways to ...
... WASHINGTON, April 7, 2011 Timing is everything. That,s ... created by the pancreas to break down food. When the ... reach the gut, where they get to work releasing and ... is wrong and the enzymes are activated too soon, they ...
Cached Biology News:Scientists exploit ash tree pest's chemical communication 2Physically active moms-to-be give babies a head start on heart health 2Physically active moms-to-be give babies a head start on heart health 3Findings may help keep pancreatic disease off the menu 2
... Background Cloning Kit includes the pZErO-1 vector ... coli. The pZErO-1 vector utilizes positive selection ... of the Zeocin resistance gene reduces the ... transformation efficiencies. The kit contains all of ...
NATIVE, ENZYME PORCINE TRYPSIN...
... S-Adenosyl-Homocysteine. S-Adenosyl Homocysteine 100%,S-Adenosyl Methionine ... 0.27%,Homocysteine ... <0.1%,L-Cysteine ... Assay Range: 0.1 ug/ml to ...
... Panomer 9 oligodeoxynucleotides ... are labeled at the ... proprietary Alexa Fluor dyes ... for assessing microarray spot ...
Biology Products: